Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ceva santé animale - torasemide - kõrge lagi diureetikumid, sulfoonamiidid, tavaline - koerad - ravi kliinilisi tunnuseid, mis on seotud südame paispuudulikkuse koerad, sealhulgas kopsu turse.

Euroopa Liit - eesti - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombotsütopeenia - antihemorraagilised ained - doptelet on näidustatud ravi raske trombotsütopeenia täiskasvanud patsientidel, kellel on krooniline maksahaigus, kes on kavandatud läbima invasiivne protseduur. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroidid, immunoglobuliinid).

Eesti - eesti - Ravimiamet

intervet international b.v. - newcastle'i tõve viirus-/paramüksoviirusvaktsiin - okulonasaalsuspensiooni lüofilisaat - 5000annus 1tk; 1000annus 1tk; 500annus 10tk

Eesti - eesti - Ravimiamet

ceva sante animale - tsefaloonium - intramammaarsuspensioon - 250mg 3g 3g 72tk; 250mg 3g 3g 20tk

Eesti - eesti - Ravimiamet

univet limited - tsefaloonium - intramammaarsuspensioon - 250mg 3g 3g 120tk

Eesti - eesti - Ravimiamet

intervet international b.v. - tsefaloonium - intramammaarsuspensioon - 250mg 3g 3g 20tk

Eesti - eesti - Ravimiamet

vetoquinol s.a. - kloksatsilliin - intramammaarsuspensioon - 600mg 3.6g 3.6g 24tk; 600mg 3.6g 3.6g 96tk; 600mg 3.6g 3.6g 48tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - hulgiskleroos - immunosupressandid - täiskasvanud patsientidel, kellel on kliinilistes või pildistamisfunktsioonides määratletud aktiivne haigus koos hulgiskleroosiga (rms). ravi täiskasvanud patsientidel varajases primaarne progresseeruv sclerosis multiplex (ppms) seoses haiguse kestus ja puude, ja koos pildistamine funktsioone iseloomulik põletikuline aktiivsus.